The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
SchillerJ.H., KimK.M., HutsonP.Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: An eastern cooperative group trial. J Clin Oncol.1996; 14: 2345–52.
2.
Perez-SolerR., GlissonB.S., LeeJ.S.Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with topoisomerase I poison topotecan. J Clin Oncol.1996; 14: 2785–90.
3.
ArdizzoniA., HansenH., DombernowskyP.Topotecan, a new active drug in second-line treatment of small–cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol.1997; 15: 2090–6.
4.
EckardtJ., GrallaR., PalmerM.C.Topotecan as second-line therapy in patients with small-cell lung cancer: A phase II study (abstract). European Society for Medical Oncology 21st Congress, Vienna Austria, 1996. Ann Oncol.1996; 7(supp 5): 513P.
5.
von PawelJ., SchillerJ.H., ShepherdF.A.Topotecan versus cyclophosphamide adriamycin and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol.1999: 17; 658–67.
6.
CreemersG.J., BolisG., GoreM.Topotecan, an active drug in second-line treatment in epithelial ovarian carcinoma: Results of a large European phase II study. J Clin Oncol.1996; 14: 3056–61.
7.
KudelkaA.P., TresukosolD., EdwardsC.L.Phase II study of intravenous topotecan as a five day infusion for refractory epithelial ovarian cancer. J Clin Oncol.1996; 14: 1552–7.
8.
ten Bokkel HuininkW.W., GoreM., CarmichaelJ.Topotecan versus paclitaxel for treatment of recurrent epithelial ovarian cancer. J Clin Oncol.1997; 15: 2183–93.
9.
HerbenV.M., ten Bokkel HuininkW.W., SchotM.E.Continuous infusion of low-dose topotecan: Pharmacokinetics and pharmacodynamics during a phase II study in patient with small cell lung cancer. Anti-Cancer Drugs.1998; 9: 411–8.
AdjeiA.A., MarksR.S., BonnerJ.A.Current guidelines for the management of small cell lung cancer. Mayo Clin Proc.1999; 74: 809–16.
12.
OzolsR.Update of the NCCN ovarian cancer practice guidelines. Oncology.1997; 11: 95–105.
13.
BurrisH.A., RothernbergM.L., KuhnJ.G.Clinical trials with topoisomerase I inhibitors. Semin Oncol.1992; 19: 663–9.
14.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
15.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
16.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
17.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of anti-emetics: Evidenced-based, clinical practice guidelines. J Clin Oncol.1999; 17; 271–94.
American Society of Clinical Oncology.American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.1994; 12: 2471–2508.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
22.
CersosimoR.J.Topotecan: A new topoisomerase I inhibiting antineoplastic agent. Ann Pharmacother.1998; 32: 1334–43.
23.
O'ReillyS., RowinskyE.K., SlichenmyerW.Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol.1996; 14: 3062–73.
24.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
25.
HerbenV.M., ten Bokkel HuininkW.W., BeijninJ.H.Clinical pharmacokinetics of topotecan. Clin Pharmacokinet.1996; 31: 85–102.
26.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24: 969–89.
27.
O'ReillyS., RowinskyE., SlichenmyerW.Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst.1996; 88: 817–24.
